GLP-1 Therapy: Which Blood Tests Are Commonly Used?

Medical & affiliate disclosure: CTX Stat provides educational laboratory information and is not a substitute for professional medical advice, diagnosis, or treatment. CTX Stat may receive compensation from some outbound provider links when an affiliate program is active; provider comparisons and rankings are based on consumer fit, effective cost, access, policies, and reputation—not commission.

GLP-1 medicines have become common in care plans for type 2 diabetes, chronic weight management, and cardiometabolic risk reduction. If you are starting or already using a medication such as semaglutide, tirzepatide, liraglutide, dulaglutide, or another incretin-based therapy, blood testing helps your clinician answer practical questions: Is glucose improving? Are the kidneys and electrolytes stable? Are cholesterol and triglyceride-related risks being addressed? Are symptoms pointing to a complication that needs urgent evaluation?

The short answer: the most common blood tests for GLP-1 therapy are A1C, fasting or random glucose, a comprehensive metabolic panel, kidney function markers such as creatinine and eGFR, liver enzymes, and a lipid panel. Depending on the person, clinicians may also order urine albumin-to-creatinine ratio, pregnancy testing, thyroid testing, pancreatic enzymes, or additional studies. These tests do not “prove” that a GLP-1 drug is safe for every individual; they provide a baseline and a way to monitor response, side effects, and related health risks.

Why blood tests are used with GLP-1 therapy

GLP-1 receptor agonists and dual GIP/GLP-1 medicines work through several mechanisms: they increase glucose-dependent insulin secretion, reduce glucagon in many settings, slow gastric emptying, and affect appetite and satiety. In real life, that means a person may experience lower glucose, weight loss, improved triglycerides, and reduced cardiometabolic risk over time—but also nausea, vomiting, constipation, dehydration, or medication interactions that need attention.

The American Diabetes Association Standards of Care describe GLP-1–based therapies as important glucose-lowering options for many adults with type 2 diabetes, particularly when weight, cardiovascular disease, or kidney disease considerations are part of the treatment plan. The same standards note medication-specific cautions, including gastrointestinal effects, pancreatitis evaluation when suspected, gallbladder disease evaluation when suspected, and kidney monitoring when severe gastrointestinal symptoms occur in people at risk.

Testing is therefore not just about the GLP-1 drug. It is about the whole clinical picture: diabetes status, kidney function, cardiovascular risk, liver health, weight-related complications, other medications, and symptoms. A person using a GLP-1 medication for type 2 diabetes and taking insulin may need different monitoring than a person using a weight-management dose without diabetes.

Common blood tests for GLP-1 therapy

Test	Why it may be ordered	How results are commonly used
A1C	Shows average blood glucose over roughly the past 2–3 months.	Tracks diabetes response to therapy and helps guide medication adjustments.
Fasting glucose or random glucose	Measures blood sugar at one point in time.	Helps identify hypoglycemia, hyperglycemia, and short-term response.
Comprehensive metabolic panel	Includes glucose, electrolytes, kidney markers, liver enzymes, albumin, and related chemistry values.	Provides a broad baseline and follow-up snapshot, especially if side effects occur.
Creatinine and eGFR	Assess kidney filtration.	Used before treatment and during illness, dehydration, kidney disease, or dose changes when clinically needed.
Electrolytes	Includes sodium, potassium, chloride, and bicarbonate.	Important if vomiting, diarrhea, poor intake, diuretics, kidney disease, or dehydration are present.
Liver enzymes	ALT, AST, alkaline phosphatase, and bilirubin can reflect liver or biliary tract stress.	Helpful for metabolic liver disease assessment and evaluation of abdominal pain or suspected gallbladder disease.
Lipid panel	Measures total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides.	Supports cardiovascular risk assessment and tracks metabolic changes with weight loss and diabetes care.
Lipase or amylase	Pancreatic enzymes.	Usually ordered when symptoms suggest pancreatitis, not as routine screening for everyone.

A1C

A1C is one of the most useful tests when GLP-1 therapy is prescribed for type 2 diabetes. It estimates average glucose exposure over the life span of red blood cells, so it changes more slowly than a home glucose reading. If the medication is effective and tolerated, A1C often moves in the desired direction over several months.

However, A1C has limitations. It can be misleading in conditions that affect red blood cells, such as certain anemias, recent blood loss, transfusion, some hemoglobin variants, advanced kidney disease, and pregnancy. The ADA’s diagnosis and classification guidance notes that A1C testing should use standardized methods and that glucose-based testing may be needed when A1C and clinical findings do not match.

Glucose testing

Fasting glucose, random glucose, home finger-stick glucose, and continuous glucose monitoring all provide more immediate information than A1C. This is especially important when GLP-1 therapy is used with insulin or a sulfonylurea, because those combinations can increase the risk of low blood sugar. GLP-1 medicines by themselves have a relatively low hypoglycemia risk because their insulin effect is glucose-dependent, but the overall risk depends on the complete medication plan.

People who do not have diabetes may not need frequent glucose checks unless symptoms, prediabetes, other medications, or clinician concerns are present. If symptoms such as shakiness, sweating, confusion, faintness, or palpitations occur, glucose testing may help determine whether low blood sugar is part of the problem.

Comprehensive metabolic panel

A comprehensive metabolic panel, often abbreviated CMP, is a common baseline test because it covers several systems in one blood draw. It includes kidney-related markers, electrolytes, glucose, calcium, albumin, total protein, bilirubin, and liver-associated enzymes. For GLP-1 therapy, the CMP is often used to establish a starting point and to evaluate symptoms such as prolonged vomiting, diarrhea, dehydration, abdominal pain, weakness, or poor oral intake.

The kidney portion of the CMP is particularly relevant because severe gastrointestinal side effects can lead to dehydration. The current Wegovy prescribing information, for example, notes postmarketing reports of acute kidney injury with semaglutide and recommends monitoring renal function in patients reporting adverse reactions that could lead to volume depletion, especially during initiation and escalation. The Zepbound prescribing information includes a similar warning for acute kidney injury due to volume depletion.

Kidney function: creatinine, eGFR, and urine albumin

Creatinine is a blood marker used to estimate glomerular filtration rate, or eGFR. eGFR is a calculated estimate of kidney filtration and is commonly reported automatically with creatinine. A normal or stable eGFR is reassuring, but it does not rule out all kidney problems.

For people with diabetes, urine albumin-to-creatinine ratio is also important. This is usually a urine test rather than a blood test, but it belongs in the GLP-1 monitoring conversation because it helps detect kidney damage that creatinine alone may miss. The ADA’s chronic kidney disease standards recommend at least annual assessment of eGFR and urinary albumin-to-creatinine ratio in all people with type 2 diabetes, regardless of treatment.

Liver enzymes and bilirubin

ALT and AST are commonly discussed as “liver enzymes,” while alkaline phosphatase and bilirubin can be helpful when bile duct or gallbladder conditions are being considered. Many people prescribed GLP-1 therapy have metabolic risk factors such as insulin resistance, obesity, dyslipidemia, or fatty liver disease, so liver chemistry results can be useful even when the medication itself is not the main concern.

GLP-1 medicines are also associated with gastrointestinal symptoms, and rapid weight loss can increase the risk of gallstones. Product labeling for semaglutide and tirzepatide includes warnings about acute gallbladder disease and recommends clinical evaluation when gallbladder disease is suspected. Blood tests alone cannot diagnose gallstones; clinicians often use symptoms, liver/biliary chemistry patterns, and imaging such as ultrasound when needed.

Lipid panel

A lipid panel measures total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides. It is not a “GLP-1 safety test” in the narrow sense, but it is commonly ordered because GLP-1 therapy is often part of a broader cardiometabolic plan. Weight loss, improved glucose control, dietary changes, and statin therapy can all change lipid results over time.

When triglycerides are very high, clinicians may pay extra attention because severe hypertriglyceridemia can raise pancreatitis risk. In that situation, the lipid panel may affect the broader risk-management plan even if it does not directly determine whether a GLP-1 medicine can be used.

Baseline vs. follow-up testing

Many clinicians order baseline testing before starting therapy, then repeat selected tests after dose escalation or after several months of treatment. The schedule varies because GLP-1 therapy is used in different situations: type 2 diabetes, obesity without diabetes, chronic kidney disease risk, cardiovascular disease risk, or combinations of these.

When testing happens	Common tests	Typical reason
Before starting	A1C or glucose, CMP, kidney function, liver enzymes, lipid panel; pregnancy test when relevant.	Establish baseline health status and guide medication choice.
During dose escalation	Glucose monitoring if diabetes medications are used; CMP or kidney/electrolyte testing if significant GI symptoms occur.	Check tolerability, hypoglycemia risk, hydration status, and kidney stability.
After 3 months or more	A1C, glucose, weight-related metabolic markers, lipid panel when clinically appropriate.	Assess response and decide whether the plan needs adjustment.
Ongoing maintenance	Individualized: A1C, kidney testing, urine albumin, lipids, liver enzymes, or other tests based on conditions.	Monitor diabetes control, kidney risk, cardiovascular risk, and medication safety.

For people with diabetes, A1C is often checked about every 3 months when therapy is changing or goals are not yet stable, then less often when results are stable and the treatment plan is not changing. For people taking GLP-1 therapy for weight management without diabetes, A1C may still be checked if there is prediabetes, a family history of diabetes, prior gestational diabetes, symptoms, or other risk factors.

Tests used when symptoms occur

Some lab tests are not routine but become important when symptoms appear. This distinction matters because over-testing can create confusing borderline results, while under-testing can miss a serious problem.

Pancreatitis evaluation: lipase and amylase

Pancreatitis is inflammation of the pancreas. Symptoms often include persistent, severe upper abdominal pain that may radiate to the back, sometimes with nausea or vomiting. GLP-1 labeling advises discontinuing the medication and evaluating appropriately if pancreatitis is suspected. In clinical practice, lipase is usually the preferred pancreatic enzyme test, with amylase sometimes added depending on the setting.

Routine lipase checks in people without symptoms are not always useful. Pancreatic enzymes can be mildly elevated for reasons other than pancreatitis, and an isolated lab result may not match the clinical picture. If you develop severe or persistent abdominal pain while using a GLP-1 medication, do not try to interpret enzymes on your own; contact a clinician promptly or seek urgent care if symptoms are severe.

Gallbladder or bile duct evaluation

Gallbladder problems may cause right upper abdominal pain, pain after fatty meals, nausea, vomiting, fever, yellowing of the skin or eyes, dark urine, or pale stools. Blood tests may include bilirubin, alkaline phosphatase, ALT, AST, and a complete blood count. Imaging is often needed because blood tests cannot reliably show whether gallstones are present.

Dehydration, kidney stress, and electrolyte imbalance

Nausea, vomiting, diarrhea, and reduced fluid intake are common reasons clinicians check a CMP or basic metabolic panel. The key values often include creatinine, eGFR, sodium, potassium, chloride, bicarbonate, and sometimes magnesium. People taking diuretics, ACE inhibitors, ARBs, NSAIDs, or other kidney-relevant medications may need extra caution during periods of poor intake or fluid loss.

Thyroid tests

Most GLP-1 users do not need routine calcitonin or thyroid ultrasound screening solely because they take a GLP-1 medication. GLP-1 and GIP/GLP-1 prescribing information includes a boxed warning about thyroid C-cell tumors observed in rodents and contraindications for people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Thyroid-stimulating hormone, or TSH, may be ordered for common reasons—fatigue, weight changes, thyroid history, abnormal exam findings—but it is not a general safety screen for the boxed warning.

How to prepare for testing

• Ask whether fasting is required. A1C does not require fasting. A fasting glucose or triglyceride-focused lipid panel may require fasting, depending on the clinician’s instructions.
• Bring a complete medication list. Include insulin, sulfonylureas, blood pressure medicines, diuretics, NSAIDs, supplements, and compounded or nonprescription products.
• Report symptoms before the draw. Vomiting, diarrhea, abdominal pain, dark urine, fever, severe constipation, or inability to keep fluids down can change what tests are appropriate.
• Do not stop prescribed medication just to “improve” labs unless instructed. Medication changes should be coordinated with the prescribing clinician.
• For home collection or direct-to-consumer testing, confirm what is included. A “metabolic panel” may not include A1C, lipids, lipase, or urine albumin unless those tests are specifically listed.

Cost, ordering, and practical tips

Costs vary widely depending on insurance, laboratory network, clinician visit requirements, draw fees, and whether testing is ordered through a medical practice, telehealth service, pharmacy clinic, or direct-to-consumer lab platform. The most useful comparison is the effective total cost: the lab price plus any required clinician consult, platform fee, blood draw fee, specimen handling fee, or follow-up fee.

If you are paying cash, compare the exact test components rather than the package name. For example, a basic metabolic panel does not provide liver enzymes, while a comprehensive metabolic panel does. A lipid panel does not include A1C. A urine albumin-to-creatinine ratio is a separate urine test. If a GLP-1 program advertises “routine labs,” look for a plain-language list of the included tests and whether abnormal results receive clinician review.

For insurance-based care, using an in-network laboratory can make a large difference. If the prescribing clinician orders labs, ask whether the lab location is in network, whether fasting is needed, and whether any tests are being ordered because of symptoms rather than routine monitoring. Symptom-driven testing may be more urgent and may be handled differently than routine preventive or chronic-care labs.

How to interpret results: practical examples

A1C is improving but fasting glucose is still high. This can happen when average glucose is improving but morning glucose remains elevated. The clinician may review meal timing, sleep, alcohol intake, other medications, dose escalation, or whether additional diabetes therapy is needed.

Creatinine increased after several days of vomiting. This may reflect dehydration or acute kidney stress. A clinician may recommend fluids, medication review, repeat labs, or urgent evaluation depending on severity and symptoms.

ALT and AST are mildly elevated. Mild liver enzyme elevations can occur with fatty liver disease, alcohol use, viral hepatitis, medications, supplements, recent intense exercise, and many other causes. The pattern and trend matter more than one isolated value.

Lipase is mildly elevated without abdominal pain. This does not automatically mean pancreatitis. Interpretation depends on symptoms, degree of elevation, imaging, other diagnoses, and clinician assessment.

Triglycerides remain high despite weight loss. Diet, alcohol, diabetes control, genetics, thyroid disease, kidney disease, and medications can all contribute. A lipid-focused plan may be needed alongside GLP-1 therapy.

When to contact a clinician urgently

Seek urgent medical advice if you have severe or persistent abdominal pain, repeated vomiting, inability to keep fluids down, signs of dehydration, fainting, confusion, yellowing of the skin or eyes, dark urine, severe constipation with abdominal swelling, or symptoms of low blood sugar that do not improve with appropriate treatment. Lab testing is helpful, but severe symptoms should not wait for routine outpatient results.

 

FAQs

What labs are usually required for GLP-1 therapy?

There is no single universal lab panel required for every person. Common baseline tests include A1C or glucose, a comprehensive metabolic panel, kidney function, liver enzymes, and a lipid panel. People with diabetes often need urine albumin-to-creatinine ratio testing as part of routine kidney risk monitoring.

Do I need blood tests if I am using GLP-1 therapy only for weight loss?

Often, yes. Even without diabetes, baseline glucose or A1C, kidney function, liver enzymes, and lipids can help assess metabolic risk and provide a comparison point if symptoms or side effects occur later. Your clinician may tailor testing based on your age, weight history, blood pressure, medications, pregnancy possibility, and medical conditions.

Can GLP-1 therapy cause low blood sugar?

By itself, GLP-1 therapy has a relatively low risk of hypoglycemia. The risk is higher when combined with insulin, sulfonylureas, or other glucose-lowering drugs. If you take those medications, your clinician may recommend home glucose monitoring or medication dose adjustments.

Should lipase be checked before starting a GLP-1 medication?

Not routinely for everyone. Some clinicians may check it in selected patients with a history of pancreatitis, high triglycerides, unexplained abdominal symptoms, or other risk factors. For most people, lipase is more useful when symptoms suggest pancreatitis.

What blood tests check for dehydration from GLP-1 side effects?

A basic or comprehensive metabolic panel can assess kidney function and electrolytes. Creatinine, eGFR, sodium, potassium, bicarbonate, and related values can help clinicians evaluate dehydration, kidney stress, and acid-base changes.

How long after starting GLP-1 therapy should labs be repeated?

Many diabetes care plans recheck A1C after about 3 months because A1C changes over time. Kidney and electrolyte testing may be repeated sooner if severe nausea, vomiting, diarrhea, dehydration, kidney disease, or medication interactions are present. Weight-management plans without diabetes may use a different schedule.

Are at-home blood tests accurate enough?

At-home or self-collected tests can be useful when performed by a qualified laboratory and when collection requirements are appropriate for the test. Some tests require venous blood, careful handling, fasting, or prompt processing. Always check whether the result is reviewed by a clinician and whether confirmatory testing is needed.

Can I order my own labs for GLP-1 monitoring?

In many states, consumers can order certain wellness or monitoring labs directly. This can be convenient, but it is not a substitute for medical oversight—especially if results are abnormal, symptoms are present, or prescription medication decisions are involved. Compare total cost and confirm exactly which tests are included before purchasing.

Sources

• American Diabetes Association: Pharmacologic Approaches to Glycemic Treatment, Standards of Care in Diabetes—2026
• American Diabetes Association: Diagnosis and Classification of Diabetes, Standards of Care in Diabetes—2026
• American Diabetes Association: Chronic Kidney Disease and Risk Management, Standards of Care in Diabetes—2026
• DailyMed: Wegovy prescribing information
• DailyMed: Ozempic prescribing information
• DailyMed: Zepbound prescribing information

Educational note: This article is for general health education and does not diagnose, treat, or replace individualized medical advice. GLP-1 therapy and related lab testing should be interpreted with a qualified healthcare professional who knows your medical history, medication list, symptoms, and treatment goals.